相似文献
1
Increasing impact of quantitative methods and modeling in establishment of bioequivalence and characterization of drug delivery.
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):552-555. doi: 10.1002/psp4.12930. Epub 2023 Feb 9.
2
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
Eur J Pharm Sci. 2020 Feb 15;143:105170. doi: 10.1016/j.ejps.2019.105170. Epub 2019 Nov 27.
3
Particle Size Distribution Equivalency as Novel Predictors for Bioequivalence.
AAPS PharmSciTech. 2018 Oct;19(7):2787-2800. doi: 10.1208/s12249-018-1121-1. Epub 2018 Aug 16.
4
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.
J Clin Pharmacol. 2019 Sep;59(9):1252-1263. doi: 10.1002/jcph.1017. Epub 2019 May 14.
5
Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
J Pharm Sci. 2019 Jan;108(1):741-749. doi: 10.1016/j.xphs.2018.11.005. Epub 2018 Nov 13.
6
Correlation between microstructure and bioequivalence in anti-HIV drug efavirenz.
Eur J Pharm Biopharm. 2015 Apr;91:52-8. doi: 10.1016/j.ejpb.2015.01.020. Epub 2015 Feb 3.
7
Bioavailability/bioequivalence of modified release drug delivery systems: which pharmacokinetic parameters to determine, single or multiple dose studies, pretests, conditions and other aspects.
Methods Find Exp Clin Pharmacol. 1992 Jul-Aug;14(6):469-82.
8
Controversy. II: Bioequivalence as an indicator of therapeutic equivalence: modeling the theoretic influence of bioinequivalence on single-dose drug effect.
J Clin Pharmacol. 1987 May-Jun;27(5):342-5. doi: 10.1002/j.1552-4604.1987.tb03029.x.
9
Bayesian modeling of multivariate average bioequivalence.
Stat Med. 2008 Jun 15;27(13):2402-19. doi: 10.1002/sim.3160.
10
Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
AAPS J. 2017 Mar;19(2):360-366. doi: 10.1208/s12248-016-0025-9. Epub 2016 Dec 21.
引用本文的文献
1
Paving the Path for Increased Technological Innovation, Strategic Decision Making and Regulatory Acceptance of Modeling and Simulation Approaches.
Pharm Res. 2025 May;42(5):727-729. doi: 10.1007/s11095-025-03868-6.
2
Integrating Quantitative Methods & Modeling and Analytical Techniques in Reverse Engineering; A Cutting-Edge Strategy in Complex Generic Development.
AAPS PharmSciTech. 2025 Mar 26;26(4):92. doi: 10.1208/s12249-025-03067-x.
3
Considering Opportunities and Challenges When Implementing the Model Master File Framework - a Meeting Report.
Pharm Res. 2025 Mar 7. doi: 10.1007/s11095-025-03839-x.
4
Application of Advanced Modeling Approaches Supporting Generic Product Development Under GDUFA for Fiscal Year 2023.
AAPS J. 2024 Apr 24;26(3):55. doi: 10.1208/s12248-024-00924-8.
5
Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers.
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):549-551. doi: 10.1002/psp4.12968. Epub 2023 Apr 27.
本文引用的文献
1
Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop.
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):624-630. doi: 10.1002/psp4.12931. Epub 2023 Feb 9.
2
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview.
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):619-623. doi: 10.1002/psp4.12920. Epub 2023 Feb 5.
3
Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective.
Adv Drug Deliv Rev. 2022 Nov;190:114526. doi: 10.1016/j.addr.2022.114526. Epub 2022 Sep 5.
4
Application of Modeling and Simulation to Identify a Shortened Study Duration and Novel Bioequivalence Metric for a Long-Acting Intrauterine System.
AAPS J. 2022 May 2;24(3):63. doi: 10.1208/s12248-022-00715-z.
5
Physiologically-Based Pharmacokinetic Modeling to Support Determination of Bioequivalence for Dermatological Drug Products: Scientific and Regulatory Considerations.
Clin Pharmacol Ther. 2022 May;111(5):1036-1049. doi: 10.1002/cpt.2356. Epub 2021 Jul 29.
6
In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products.
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):359-370. doi: 10.1002/psp4.12413. Epub 2019 May 21.
7
Innovation for Generic Drugs: Science and Research Under the Generic Drug User Fee Amendments of 2012.
Clin Pharmacol Ther. 2019 Apr;105(4):878-885. doi: 10.1002/cpt.1364. Epub 2019 Mar 2.
8
Generating Model Integrated Evidence for Generic Drug Development and Assessment.
Clin Pharmacol Ther. 2019 Feb;105(2):338-349. doi: 10.1002/cpt.1282. Epub 2019 Jan 20.
Zotero 插件
